State Street
MBX

State Street’s MBX Biosciences MBX Stock Holding History

State Street’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.5M Buy
787,208
+114,468
+17% +$3.89M ﹤0.01% 2161
2025
Q4 		$21.2M Buy
672,740
+353,466
+111% +$8.58M ﹤0.01% 2242
2025
Q3 		$5.59M Buy
319,274
+54,155
+20% +$724K ﹤0.01% 2962
2025
Q2 		$3.03M Buy
265,119
+87,899
+50% +$895K ﹤0.01% 3164
2025
Q1 		$1.31M Buy
177,220
+34,571
+24% +$366K ﹤0.01% 3373
2024
Q4 		$2.63M Buy
+142,649
New +$3.04M ﹤0.01% 3229

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street's MBX Position: Q1 2026 in Review

State Street increased its MBX Biosciences (MBX) stake by 17% in Q1 2026, buying an estimated $3.89M and bringing the position to 787,208 shares worth $23.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2161.

State Street first reported a position in MBX in Q4 2024 and has held it in 6 quarters since. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • State Street held 787,208 shares of MBX Biosciences worth $23.5M as of Q1 2026.
  • State Street bought 114,468 MBX Biosciences shares in Q1 2026, an estimated $3.89M.
  • MBX Biosciences made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2161 holding.
  • State Street first reported a position in MBX Biosciences in Q4 2024 and has held it in 6 quarters since.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.